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Abstract
Background: A malaria vaccine could be an important addition to current control strategies. We report the safety and
vaccine efficacy (VE) of the RTS,S/AS01 vaccine during 18 mo following vaccination at 11 African sites with varying malaria
transmission.
Methods and Findings: 6,537 infants aged 6–12 wk and 8,923 children aged 5–17 mo were randomized to receive three
doses of RTS,S/AS01 or comparator vaccine. VE against clinical malaria in children during the 18 mo after vaccine dose 3
(per protocol) was 46% (95% CI 42% to 50%) (range 40% to 77%; VE, p,0.01 across all sites). VE during the 20 mo after
vaccine dose 1 (intention to treat [ITT]) was 45% (95% CI 41% to 49%). VE against severe malaria, malaria hospitalization, and
all-cause hospitalization was 34% (95% CI 15% to 48%), 41% (95% CI 30% to 50%), and 19% (95% CI 11% to 27%),
respectively (ITT). VE against clinical malaria in infants was 27% (95% CI 20% to 32%, per protocol; 27% [95% CI 21% to 33%],
ITT), with no significant protection against severe malaria, malaria hospitalization, or all-cause hospitalization. Post-
vaccination anti-circumsporozoite antibody geometric mean titer varied from 348 to 787 EU/ml across sites in children and
from 117 to 335 EU/ml in infants (per protocol). VE waned over time in both age categories (Schoenfeld residuals p,0.001).
The number of clinical and severe malaria cases averted per 1,000 children vaccinated ranged across sites from 37 to 2,365
and from 21 to 49, respectively; corresponding ranges among infants were 210 to 1,402 and 213 to 37, respectively (ITT).
Meningitis was reported as a serious adverse event in 16/5,949 and 1/2,974 children and in 9/4,358 and 3/2,179 infants in
the RTS,S/AS01 and control groups, respectively.
Conclusions: RTS,S/AS01 prevented many cases of clinical and severe malaria over the 18 mo after vaccine dose 3, with the
highest impact in areas with the greatest malaria incidence. VE was higher in children than in infants, but even at modest
levels of VE, the number of malaria cases averted was substantial. RTS,S/AS01 could be an important addition to current
malaria control in Africa.
Trial registration: http://www.ClinicalTrials.gov NCT00866619
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Introduction
Considerable gains have been made in the control of malaria
during the past decade as a result of improved diagnosis,
introduction of effective treatment with artemisinin combination
therapy (ACT), and widespread deployment of insecticide-treated
nets (ITNs) [1,2]. It is estimated that malaria mortality fell by 45%
in all age groups and by 51% in children under 5 y of age between
2000 and 2012. However, in 2012 Plasmodium falciparum still
caused an estimated 207 million cases of malaria and 627,000
deaths, mostly in young children in sub-Saharan Africa [3], and
the gains that have been made recently in malaria control are
threatened by emerging insecticide and drug resistance [4,5]. New
interventions are required if malaria is to be finally contained in
the large areas of Africa where malaria transmission remains high
[6]. A malaria vaccine is needed to complement current
interventions.
RTS,S/AS01 is currently the most advanced malaria vaccine
candidate and the first to undergo large-scale phase 3 evaluation in
Africa. The RTS,S/AS01 malaria vaccine, which targets the pre-
erythrocytic stage of P. falciparum, induces humoral and cellular
immune responses to the circumsporozoite protein present on the
surface of sporozoites and liver stage schizonts. RTS,S was
identified as a potential candidate for further development
following encouraging results in an experimental challenge study
[7]. Subsequent phase 2 studies in adults and children showed that
the vaccine was safe, was immunogenic, and provided protection
against clinical episodes of malaria in the range of 30%–60% [8–
10]. The AS01 adjuvant was shown to be more immunogenic than
the AS02 adjuvant used in initial studies [11], and RTS,S/AS01
was well tolerated and efficacious [12–14]. These encouraging
phase 2 trial results led to the decision to conduct a large-scale
phase 3 clinical trial involving 15,460 children recruited at 11 sites
in seven countries across Africa. We have reported previously
overall vaccine efficacy (VE) and safety during 12 mo of follow-up
[15,16]. The first analysis, conducted in 6,000 children aged 5–
17 mo at the time of first vaccination, showed that, per protocol,
RTS,S/AS01 gave 56% (97.5% CI 51% to 60%) protection
against the first or only episode of clinical malaria and 47% (95%
CI 22% to 64%) efficacy against severe malaria during 12 mo of
follow-up. VE was lower in young infants vaccinated at the age of
6–12 wk when RTS,S/AS01 was given at the same time as routine
Expanded Program on Immunization (EPI) vaccines; VE against
first or only clinical malaria episode in the per-protocol population
was 31% (97.5% CI 24% to 38%) against clinical malaria and
37% (95% CI 5% to 58%) against severe malaria. The vaccine was
immunogenic and generally safe, although an imbalance in cases
of meningitis was seen in both age categories between participants
who received RTS,S/AS01 and the control vaccine (rabies vaccine
for children 5–17 mo at enrollment and meningococcal C
conjugate vaccine for infants 6–12 wk at enrollment) [15,16].
The objectives of the analyses reported in this paper were
determination of VE in both age categories of children during
18 mo of follow-up, just prior to administration of a booster dose of
RTS,S/AS01 and, for the first time, an analysis of variations in the
immunogenicity and VE of RTS,S/AS01 by study site. Site-specific
measurements of VE provide insight into the determinants of the
overall estimates of VE and are used to calculate the number of
clinical and severe malaria cases averted, important measures of
public health impact that will be useful to policy makers.
Methods
The trial protocol was approved by the ethical review board at
each study center and partner institution and by the national
regulatory authority in each country (Table S1A). The study was
conducted in accordance with Good Clinical Practice guidelines
[17].
Study Design
Trial methods have been reported previously [15,16,18] and are
available in the Text S1. This randomized, controlled, double-
blind trial of the candidate malaria vaccine RTS,S/AS01 is being
conducted at 11 sites in seven African countries (Figure 1). The
trial is designed to evaluate VE, safety, and immunogenicity
during an average period of 49 mo (range: 41–55 mo) after the
first dose of study vaccine in children and an average period of
41 mo (range: 32–48 mo) after the first dose of study vaccine in
young infants. Informed consent was obtained from the partici-
pants’ parents or guardians. Children with a moderate or severe
illness; a major congenital defect; malnutrition requiring hospital-
ization; a hemoglobin concentration ,5.0 g/dl, or ,8 g/dl with
clinical signs of decompensation; a history of atypical febrile
seizures; a neurological disorder; or WHO stage III or stage IV
HIV disease at the time of presentation were ineligible for
enrollment. ITNs were provided or made available to any child
who presented for screening. Reported ITN use or protection by
indoor residual spraying was documented during a home visit
12 mo after the third dose of study vaccine. Anthropometric
measurements were taken at enrollment and 1 and 18 mo after the
third dose of study vaccine.
Randomization and Vaccination
From March 27, 2009, through January 31, 2011, 15,460 young
infants and children were assigned randomly to one of three
groups in a 1:1:1 ratio. One group received RTS,S/AS01 followed
by a booster dose 18 mo after completing the primary vaccination
series, a second group received the RTS,S/AS01 primary
vaccination series without a booster, and the third group received
comparator vaccines, rabies vaccine (VeroRab, Sanofi-Pasteur) for
children or meningococcal C conjugate vaccine (Menjugate,
Novartis) for young infants. This analysis combines the first and
second groups (referred to as the RTS,S/AS01 group) and
compares this with the third (control) group, prior to the
administration of the booster dose in the first group (Figure S1).
Young infants received the study vaccine at the same time as EPI
vaccines.
Surveillance for Clinical and Severe Malaria
Malaria was detected by passive surveillance. Clinical malaria
was defined as an illness accompanied by a temperature $37.5uC
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and P. falciparum asexual parasitemia (.5,000 parasites/mm3) or
as an algorithm-defined case of severe malaria. Other case
definitions are presented in Tables 1, 2, S2, and S5.
Safety Surveillance
Data on serious adverse events (SAEs) were collected by passive
surveillance. SAE classification was made using all available
clinical evidence, and was not bound by stringent laboratory or
diagnostic criteria. Verbal autopsies were conducted on deaths
that occurred outside a hospital. SAEs were coded from clinician-
assigned diagnoses according to the preferred terms of the Medical
Dictionary for Regulatory Activities (MedDRA) [19].
Immunogenicity
Anti-circumsporozoite (anti-CS) antibodies were measured by
ELISA in the first 200 participants in each age category at each
study site at enrollment and 1 mo after the third dose of vaccine.
The threshold for a positive titer was 0.5 EU/ml [20].
Figure 1. Study sites and malaria endemicity. Adapted from Hay et al. [34]. The location of each participating study site is shown on this
previously published map showing the spatial distribution of P. falciparum (Pf) malaria endemicity. The data are the model-based geostatistical point
estimates of the annual mean P. falciparum parasite rate (PR) age-standardized for 2–10 y for 2007 within the stable spatial limits of P. falciparum
malaria transmission, displayed as a continuum of yellow to red from 0%–100% (see map legend). The rest of the land area was defined as unstable
risk (medium grey) or no risk (light grey). Nanoro, Burkina Faso, has highly seasonal malaria transmission.
doi:10.1371/journal.pmed.1001685.g001
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Laboratory and Radiologic Procedures
Laboratory and radiologic procedures are described fully in
Text S1. All blood smears were read by two independent
microscopists, and parasite densities were determined using
standardized procedures. Discrepant findings were resolved
according to a formal algorithm. Standardized, automated
biochemical and hematological methods were used. Standard
microbiology methods for blood and CSF culture were followed
using automated Bactec incubators and pediatric bottles (Bactec
BD Diagnostic Systems). A rigorous external quality assurance
process was implemented at all sites for all laboratory procedures
that produced study end points.
Statistical Analysis
Efficacy against all episodes of malaria was analyzed by negative
binomial regression with follow-up time as offset, allowing for
interdependence between episodes within the same individual.
Overall estimates were adjusted for study site as a fixed effect,
whereas site estimates were unadjusted for covariates. Inter-site
variation was evaluated by site interaction terms, and prespecified
univariate analyses and multivariate models were used to explore
the impact of covariates on post-vaccination anti-CS responses or
on VE. Transmission intensity was defined in the models as the
malaria incidence in control children or control young infants,
depending on the age category included in the model. VE against
all other clinical end points was estimated as a relative risk (RR)
reduction with Fisher’s exact p-values. VE over time was evaluated
by Schoenfeld residuals p-values, Andersen-Gill Cox models with
time-varying covariates, and incidence reduction by 6-mo periods.
Vaccine impact was calculated as the difference in incidence
between the RTS,S/AS01 and control groups, expressed per
1,000 children vaccinated for each 6-mo period of follow-up. The
cumulative number of cases averted over 18 mo was calculated by
summing the number of cases averted for each 6-mo follow-up
period. The per-protocol population included all participants who
received three doses of vaccine and contributed to efficacy
surveillance, starting 14 d after the third dose. The intention-to-
treat (ITT) population included all participants who received at
least one dose of vaccine. The more specific primary case
definition of clinical malaria was used for determination of VE.
VE calculated using secondary case definitions is also reported.
The co-primary end points of VE in infants and children,
presented in prior publications, were described with 97.5% CIs; all
other VE end points are presented with 95% CIs. A sensitive
secondary case definition (measured or reported fever in the prior
24 h and P. falciparum parasite density .0 parasites/mm3) was
used for the evaluation of the impact of RTS,S/AS01 on clinical
malaria because, in clinical practice, sick children who present to a
health facility with any level of malaria parasitemia receive
treatment for malaria. Data were censored at the time of
administration of a booster dose, 20 mo after dose 1, or at the
date of emigration, withdrawal of consent, or death.
Results
Study Population
Overall, 8,923 children and 6,537 young infants were enrolled.
All randomized children and young infants were included in the
ITT population, while 6,885 (77%) children and 6,003 (92%)
young infants were included in the per-protocol population
(Figures 2 and 3; Table S3). Baseline characteristics were similar
in the two study groups but differed by site. ITN use was 78% in
children and 86% in young infants (Figure S2, ITT). Malaria
incidence in young infants in the control group, an approximation
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of the force of infection, ranged across sites from 0.03 to 4.27
episodes per infant per year (Table S4, per protocol).
Vaccine Efficacy in Children
The incidence of all episodes of clinical malaria meeting the
primary case definition during the 18 mo of follow-up in the per-
protocol population was 0.69/person-year in the RTS,S/AS01
group and 1.17/person-year in the control group, resulting in a
VE of 46% (95% CI 42% to 50%), with overall estimates of VE
consistent across case definitions and with the ITT analysis (ITT,
VE=45% [95% CI 41% to 49%]) (Tables 1 and S5; Figures 4, 5,
and S3). Significant heterogeneity in VE was seen across sites, with
VE ranging from 40% to 77% (interaction test, p,0.001; VE, p,
0.01 at all sites). VE in the ITT population ranged across sites
from 41% to 70%. Analysis of site-specific VE in the per-protocol
population did not suggest that this heterogeneity was driven by
variations in transmission intensity (interaction between study
group and transmission intensity, p=0.66). Lower VE was
associated with moderate anemia at baseline (p= 0.04) (Table
S6). VE varied over time, being highest close to vaccination
(Schoenfeld residuals p,0.001) (Figure S4), but it persisted
throughout the observation period. The reduction in the incidence
of clinical malaria by 6-mo periods was 68% (95% CI 64% to
72%) during months 1–6, 41% (95% CI 36% to 46%) during
months 7–12, and 26% (95% CI 19% to 33%) during months 13–
18 after vaccine dose 3. Corresponding values in the ITT
population were 60% (95% CI 56% to 64%), 41% (95% CI
36% to 46%), and 28% (95% CI 21% to 35%) (Figures S5 and
S6). VE against clinical malaria and severe malaria during the first
12 mo of follow-up is presented in Figure S8 and Table S15. VE
against prevalent parasitemia, 18 mo after vaccination, was 31%
(95% CI 17% to 42%) (ITT, VE=29% [95% CI 15% to 40%])
(Table S7). VE was 36% (95% CI 15% to 51%) against severe
malaria (ITT, VE against severe malaria = 34% [95% CI 15% to
48%]), 42% (95% CI 29% to 52%) against malaria hospitalization
(ITT, VE against malaria hospitalization = 41% [95% CI 30% to
50%]), and 19% (95% CI 9% to 28%) against all-cause
hospitalization (ITT, VE against all-cause hospitalization = 19%
[95% CI 11% to 27%]) (Table 1). The incidence of severe malaria
by 6-mo periods is shown in Figure S5.
During the 18-mo follow-up period, the number of cases of
clinical malaria averted per 1,000 children vaccinated with
RTS,S/AS01 in the ITT population ranged across sites from 37
to 2,365 (average for the 11 study sites: 829), and the number of
severe malaria cases averted ranged from 21 to 49 (average across
all sites: 18) (Figures 6–11; Table S8). The number of malaria
hospitalizations averted per 1,000 children vaccinated ranged
from 0 to 138 across sites (average across all sites: 43), and all-
cause hospitalizations averted ranged from 23 to 132 (average
across all sites: 52) during the same period (Table S8). Mortality
was low; 107 children (1.2%) died during the observation period,
74/5,949 (1.2%) children in the RTS,S/AS01 group and 33/
2,974 (1.1%) in the control group. VE was not demonstrated
against all-cause mortality, malaria mortality, hospitalized pneu-
monia, septicemia, or prevalent anemia, nor was there a
detectable effect on childhood nutritional status or growth (Tables
S7, S9, and S10; Figure S7).
Vaccine Efficacy in Young Infants
The incidence of all episodes of clinical malaria meeting the
primary case definition during the 18 mo of follow-up in the per-
protocol population was 0.71/person-year in the RTS,S/AS01
group and 0.92/person-year in the control group, resulting in a
VE of 27% (95% CI 20% to 32%), with overall estimates of VE
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consistent across case definitions and the ITT analysis (ITT,
VE=27% [95% CI 21% to 33%]) (Tables 2 and S5; Figures 12,
13, and S3). VE did not differ by study site (interaction between
study group and site, p= 0.17). VE waned over time (Schoenfeld
residuals p,0.001). The reduction in incidence of clinical malaria
by 6-mo period was 47% (95% CI 39% to 54%) during months 1–
6, 23% (95% CI 15% to 31%) during months 7–12, and 12%
(95% CI 1% to 21%) during months 13–18 following dose 3.
Corresponding values in the ITT population were 44% (95% CI
37% to 50%), 23% (95% CI 15% to 31%), and 13% (95% CI 2%
to 22%) (Figures S5 and S6). VE was 15% (95% CI 220% to
39%) against severe malaria (ITT, VE against severe malaria = 8%
[95% CI 226% to 33%]), 17% (95% CI 27% to 36%) against
malaria hospitalization (ITT, VE against malaria hospitaliza-
tion= 13% [95% CI 210% to 31%]), and 6% (95% CI 27% to
17%) against all-cause hospitalization (ITT, VE against all-cause
hospitalization = 5% [95% CI 27% to 15%]). A statistically non-
significant increase in the incidence of severe malaria was observed
in RTS,S/AS01 recipients in the last 6 mo of follow-up (p=0.17)
(Figure S5).
The number of cases of clinical malaria averted per 1,000 young
infants vaccinated with RTS,S/AS01 in the ITT population
ranged across sites from 210 to 1,402 (average for the 11 study
sites: 449), and the number of severe malaria cases averted ranged
from 213 to 37 (average across all sites: 6) during the 18-mo
follow-up period (Figures 6–9, 14, and 15; Table S8). One
hundred seventeen young infants (1.8%) died during the 20-mo
observation period, 83/4,358 (1.9%) infants in the RTS,S/AS01
group and 34/2,179 (1.6%) in the control group. VE was not
demonstrated against all-cause mortality, malaria mortality,
hospitalized pneumonia, septicemia, or prevalent anemia, nor
was there a detectable effect on nutritional status or growth
(Tables S7, S9, and S10).
Immunogenicity
In children, post-vaccination anti-CS antibody geometric mean
titer (GMT) varied from 348 to 787 EU/ml across sites in the per-
protocol population (Figures 16 and 17; Table S16), but post-
vaccination titers did not explain the differences in level of
protection (p= 0.24) (Table S11). Previous hepatitis B vaccination
was not associated with a higher post-vaccination anti-CS
antibody response (p=0.73; Table S12). However, younger age
at the time of vaccination (5–11 mo versus 12–17 mo) and living
in a higher transmission setting were associated significantly with
higher post-vaccination anti-CS responses (p,0.001 and p,0.001,
respectively) (Table S12). Young infants had a lower post-
Figure 2. CONSORT diagram of children aged 5–17 mo at enrollment and followed until 18 mo post-vaccination. aOne child enrolled
in the 5–17-mo age category who was reported previously to have received three doses of study vaccine, and was included in the per-protocol
analyses reported previously, had received only the first and second doses of study vaccine. bThe date of birth of three children who were included in
the per-protocol analysis reported previously was corrected, and these children were identified as ‘‘out of age range’’ when they received the first
dose of study vaccine. These three children were excluded from the per-protocol analyses reported here. CW, consent withdrawal.
doi:10.1371/journal.pmed.1001685.g002
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vaccination anti-CS antibody GMT than children (anti-CS
antibody GMT range across sites: 117 to 335 EU/ml, per-
protocol population), and, in contrast to what was observed in
children, higher anti-CS antibody titers were associated with lower
malaria incidence (p,0.001) (Figures 18 and 19; Tables S11 and
S16). Younger age (6 wk versus 7–12 wk) and the presence of anti-
CS antibodies prior to vaccination were associated with a lower
post-vaccination anti-CS antibody response (p=0.003 and p,
0.001, respectively) (Tables S12 and S13). A graphic depiction of
the relationships between anti-CS antibody GMT, malaria
incidence, and VE is shown in Figure 20.
Safety
SAEs were less frequent in the children vaccinated with RTS,S/
AS01 than in control children: 18.6% (95% CI 17.6% to 19.6%)
versus 22.7% (95% CI 21.2% to 24.3%), while no difference in
frequency was found between vaccinated and control young
infants: 22.0% (95% CI 20.8% to 23.3%) versus 23.1% (95% CI
21.3% to 24.9%) (Table S14). The previously reported imbalance
in the incidence of meningitis persisted [15,16]. Meningitis was
reported as an SAE in 17 children (16 cases among the 5,949
children in the RTS,S/AS01 group and one case among the 2,974
children in the control group [RR=8.0 (95% CI 1.1 to 60.3)]). No
pathogen was identified in 11 cases, ten in the RTS,S/AS01 group
and one in the control group. A pathogen was identified in six
cases (four meningococcal, one pneumococcal, and one Haemoph-
ilus influenzae), all in the RTS,S/AS01 group. Six children with
reported meningitis died, five in the RTS,S/AS01 group and one
in the control group. Meningitis was reported as an SAE in 12
young infants (nine cases among 4,358 young infants in the
RTS,S/AS01 group and three among 2,179 in the control group
[RR=1.50 (95% CI 0.41 to 5.55)]). No pathogen was identified in
five cases, three in the RTS,S/AS01 group and two in the control
group. A pathogen was identified in seven cases (four pneumo-
coccus and three salmonella), six in the RTS,S/AS01 group and
one in the control group. Four infants with reported meningitis
died, two in the RTS,S/AS01 group and two in the control group.
Meningitis cases were not temporally related to vaccination
(Figure S9A). Most study sites reported 1–3 cases of meningitis
during the 18-mo follow-up period, while the site in Lilongwe,
Figure 3. CONSORT diagram of infants aged 6–12 wk at enrollment followed until 18 mo post-vaccination. aScreening data had not
been reported before the database freeze for the analysis published in 2011 for 22 infants in the 6–12-wk age category, and these participants were
not included in the 2011 CONSORT chart. bOne infant enrolled in the 6–12-wk age category who was reported to have received three doses of study
vaccine (RTS,S/AS01 or comparator vaccine) was included in the per-protocol analyses reported previously, but was subsequently found to have
received only the first dose of study vaccine. cTwo infants enrolled in the 6–12-wk age category who had been reported as ‘‘attending Visit 16 (12
months post dose-3)’’ in the 2012 CONSORT chart are reported as ‘‘migrated/lost to follow-up’’ in this CONSORT chart. In addition, one infant who
was reported as ‘‘migrated/lost to follow-up’’ in the 2012 CONSORT chart has been recorded as ‘‘consent withdrawal’’ in this CONSORT chart [15].
doi:10.1371/journal.pmed.1001685.g003
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Malawi, reported 11 cases and the site in Kombewa, Kenya,
reported five cases (Figure S9B). An overview of the analyses
reported here is given in Table S17.
Discussion
RTS,S/AS01 provided protection against a range of predefined
end points, including clinical and severe malaria, over an 18-mo
follow-up period among children aged 5–17 mo at first vaccina-
tion across a wide range of malaria transmission settings. VE
against clinical malaria was 40% or higher in each setting but
varied significantly between sites. In contrast to previous phase 2
trials, which found that efficacy decreased with increasing
exposure [21,22], the variation in VE between study sites seen
in this trial could not be explained by differences in the intensity of
malaria transmission between sites, as measured by the incidence
of clinical malaria in control children or control young infants
applied as an average transmission level for all participants at a
given site. However, there are several caveats to this finding. First,
the presence of moderate anemia at enrollment, which may reflect
malaria exposure at the individual level, was negatively associated
with VE. Second, in children, while there was no correlation found
between VE and transmission in a multivariate model, VE
appeared higher at sites with a lower incidence of malaria
(Figure 4). Differences in the incidence of clinical malaria between
sites may be influenced by various genetic and environmental
factors independent of the transmission level. Differences in anti-
CS antibody GMT across sites did not explain differences in
efficacy.
VE against clinical malaria was lower in young infants than in
children. Severe malaria was more frequent, although the
difference was not significant statistically, among young infant
RTS,S/AS01 recipients compared with controls during the final
follow-up period in this analysis, 12–18 mo after dose 3. This
could be a chance finding or could indicate that the vaccine
interfered with the acquisition of natural immunity [23], an effect
perhaps compounded by prompt access to diagnosis and
treatment. Further follow-up is planned, and will include close
monitoring of the 1/3 of participants who received the RTS,S/
AS01 primary vaccination series but not the RTS,S/AS01 booster
dose.
The current analysis has provided some clues as to why young
infants respond less effectively to RTS,S/AS01 than children.
Maternal antibodies are likely to have played a role, as young
infants with detectable anti-CS antibodies at enrollment had a
lower post-vaccination anti-CS response than young infants
without detectable anti-CS antibodies at enrollment, and a high
post-vaccination anti-CS antibody titer was associated with VE in
young infants. However, maternal antibodies cannot explain fully
the lower anti-CS response in young infants, as those without
detectable maternally derived anti-CS antibodies still had a lower
post-vaccination anti-CS antibody GMT than did vaccinated
children. Immune interference due to administration of RTS,S/
AS01 at the same time as EPI vaccines remains a possible factor.
The fact that phase 2 trials showed that co-administration in one
setting was associated with lower anti-CS responses than staggered
administration in another setting supports this hypothesis [9,10]. A
suppressive effect from exposure to malaria antigens in utero
Figure 4. Vaccine efficacy against all episodes of clinical malaria (primary case definition) during an 18-mo follow-up period after
dose 3 in children 5–17 mo of age at enrollment, ordered by increasing malaria incidence at each study site (per-protocol
population). Interaction p-value = 0.0006. The size of each blue square reflects the relative number of participants enrolled at each study site; the
horizontal bars show the lower limit (LL) and upper limit (UL) of the 95% confidence interval. Study sites are ordered from lowest (Kilifi) to highest
(Siaya) incidence of clinical malaria, defined as a measured or reported fever within previous 24 h and parasite density .0 parasites/mm3 (i.e., clinical
malaria secondary case definition), measured in control infants 6–12 wk of age at enrollment during 12 mo of follow-up. VE is VE against all episodes
of clinical malaria meeting the primary case definition, unadjusted for covariates. Clinical malaria primary case definition: illness in a child brought to a
study facility with a temperature of $37.5uC and P. falciparum asexual parasitemia at a density of .5,000 parasites/mm3 or a case of malaria meeting
the primary case definition of severe malaria.
doi:10.1371/journal.pmed.1001685.g004
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might be more marked in young infants than in older children,
who have had a longer period to acquire immunity [24,25].
Finally, the immature immune system of young infants may not
respond as well as the immune system of older children. In
contrast with findings from a phase 2 trial [26], we found no
evidence that priming with hepatitis B vaccine in children
explained their enhanced anti-CS antibody response.
VE waned over time in both young infants and children, as
reported previously [15,16]. An analysis by 6-mo period showed
that the vaccine provided protection against clinical malaria
throughout the follow-up period, but that there was a progressive
decline in efficacy. However, these analyses need to be treated
with caution; although the study groups were well matched during
the first 6-mo period, this was not the case subsequently as
children in the control group experienced more clinical malaria
than children in the RTS,S/AS01 group, and thereby may have
acquired natural immunity, making the vaccine appear less
effective by comparison. It will be important to determine whether
VE can be restored by a vaccine booster dose, which has been
given after the 18-mo follow-up to half of the RTS,S/AS01
recipients.
The trial was conducted to a high ethical and clinical standard,
with harmonization of procedures across sites [27,28]. Nonetheless,
some anomalous findings were noted. The lack of VE among young
infants in Kintampo, Ghana, despite 47% VE among children and
a post-vaccination anti-CS antibody GMT within the range seen at
other sites, was unexpected, as was the lack of efficacy against
prevalent malaria infection 18 mo post-vaccination in children at
Siaya, Kenya. These may be chance findings but warrant further
observation.
Conducting this trial to high standards required facilitating
access of trial participants to both outpatient and inpatient care;
purchasing additional clinical and laboratory equipment; ensuring
reliable supplies of essential medications, oxygen, and blood; and
increasing clinical staffing. Consequently, mortality was very low
in both study arms. This may explain why, in contrast to the
results of trials of other effective malaria control tools, such as
ITNs or prophylactic drugs, we did not find any impact of RTS,S/
AS01 on overall mortality [29,30] or on nutritional status [31].
Neither did we find an impact of the vaccine on the incidence of
hospitalized pneumonia or septicemia. The impact of RTS,S/
AS01 on mortality and co-infections might be greater were the
vaccine to be deployed in non-trial situations, where prompt, high-
quality care is less readily available.
The observed interaction between moderate anemia and
decreased VE in older children is intriguing. As stated
previously, anemia may be a sensitive indicator of individual
exposure to malaria. Alternatively, anemia might indicate active
malaria infection, which can interfere with the development of a
robust immune response to vaccination [32]. Helminth infection
is another frequent cause of anemia in toddlers and young
children in sub-Saharan Africa, and helminth infection can also
result in a reduced immunological response to vaccination [33].
Malnutrition is frequently associated with anemia, but malnu-
trition was not found to be a determinant of VE in our
multivariate model.
Figure 5. Vaccine efficacy against all episodes of clinical malaria (primary case definition) during an 18-mo follow-up period after
dose 3 in children 5–17 mo of age at enrollment, ordered by increasing malaria incidence at each study site (intention-to-treat
population). Interaction p-value = 0.8100. The size of each blue square reflects the relative number of participants enrolled at each study site; the
horizontal bars show the lower limit (LL) and upper limit (UL) of the 95% confidence interval. Study sites are ordered from lowest (Kilifi) to highest
(Siaya) incidence of clinical malaria, defined as a measured or reported fever within previous 24 h and parasite density .0 parasites/mm3 (i.e., clinical
malaria secondary case definition), measured in control infants 6–12 wk of age at enrollment during 12 mo of follow-up. VE is VE against all episodes
of clinical malaria meeting the primary case definition, unadjusted for covariates. Clinical malaria primary case definition: illness in a child brought to a
study facility with a temperature of $37.5uC and P. falciparum asexual parasitemia at a density of .5,000 parasites/mm3 or a case of malaria meeting
the primary case definition of severe malaria.
doi:10.1371/journal.pmed.1001685.g005
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Figure 6. Number of cases of clinical malaria (secondary case definition) averted per 1,000 participants vaccinated during an 18-mo
follow-up period (per-protocol population). Clinical malaria secondary case definition: illness in a child brought to a study facility with a
measured temperature of $37.5uC or reported fever within the last 24 h and P. falciparum asexual parasitemia at a density of.0 parasites/mm3. This
definition was used for this analysis because during routine clinical practice these children would normally receive a full course of anti-malarial
treatment.
doi:10.1371/journal.pmed.1001685.g006
Figure 7. Number of cases of severe malaria (secondary case definition) averted per 1,000 participants vaccinated during an 18-mo
follow-up period (per-protocol population). Severe malaria secondary case definition: P. falciparum asexual parasitemia at a density of .5,000
parasites/mm3 with one or more markers of disease severity, including cases in which a coexisting illness was present or could not be ruled out.
Markers of severe disease were prostration, respiratory distress, a Blantyre coma score of #2 (on a scale of 0 to 5, with higher scores indicating a
higher level of consciousness), two or more observed or reported seizures, hypoglycemia, acidosis, elevated lactate level, or a hemoglobin level of ,
5 g/dl. Coexisting illnesses were defined as radiographically proven pneumonia, meningitis established by analysis of cerebrospinal fluid, bacteremia,
or gastroenteritis with severe dehydration.
doi:10.1371/journal.pmed.1001685.g007
RTS,S/AS01 Malaria Vaccine Trial: 18 Months Follow-up
PLOS Medicine | www.plosmedicine.org 12 July 2014 | Volume 11 | Issue 7 | e1001685
Figure 8. Number of cases of clinical malaria (secondary case definition) averted per 1,000 participants vaccinated during a 20-mo
follow-up period (intention-to-treat population). Clinical malaria secondary case definition: illness in a child brought to a study facility with a
measured temperature of $37.5uC or reported fever within the last 24 h and P. falciparum asexual parasitemia at a density of.0 parasites/mm3. This
definition was used for this analysis because during routine clinical practice these children would normally receive a full course of anti-malarial
treatment.
doi:10.1371/journal.pmed.1001685.g008
Figure 9. Number of cases of severe malaria (secondary case definition) averted per 1,000 participants vaccinated during a 20-mo
follow-up period (intention-to-treat population). Severe malaria secondary case definition: P. falciparum asexual parasitemia at a density of .
5,000 parasites/mm3 with one or more markers of disease severity, including cases in which a coexisting illness was present or could not be ruled out.
Markers of severe disease were prostration, respiratory distress, a Blantyre coma score of #2 (on a scale of 0 to 5, with higher scores indicating a
higher level of consciousness), two or more observed or reported seizures, hypoglycemia, acidosis, elevated lactate level, or a hemoglobin level of ,
5 g/dl. Coexisting illnesses were defined as radiographically proven pneumonia, meningitis established by analysis of cerebrospinal fluid, bacteremia,
or gastroenteritis with severe dehydration.
doi:10.1371/journal.pmed.1001685.g009
RTS,S/AS01 Malaria Vaccine Trial: 18 Months Follow-up
PLOS Medicine | www.plosmedicine.org 13 July 2014 | Volume 11 | Issue 7 | e1001685
Figure 10. Number of cases of clinical malaria (secondary case definition) averted during an 18-mo follow-up period in children 5–
17 mo of age at enrollment, by study site, ordered by increasing malaria incidence at each site (per-protocol population). Clinical
malaria secondary case definition: illness in a child brought to a study facility with a measured temperature of $37.5uC or reported fever within the
last 24 h and P. falciparum asexual parasitemia at a density of .0 parasites/mm3. This definition was used for this analysis because during routine
clinical practice these children would normally receive a full course of anti-malarial treatment. Study sites are ordered from lowest (Kilifi) to highest
(Siaya) incidence of clinical malaria, defined as a measured or reported fever within previous 24 h and parasite density .0 parasites/mm3 (i.e., clinical
malaria secondary case definition), measured in control infants 6–12 wk of age at enrollment during 12 mo of follow-up. A deviation pertaining to
study vaccine exposure to temperatures outside recommended ranges resulted in the exclusion from the per-protocol population of all children 5–
17 mo old enrolled in Manhic¸a, Mozambique, therefore no data are presented in this age category for Manhic¸a (asterisk).
doi:10.1371/journal.pmed.1001685.g010
Figure 11. Cases of clinical malaria (secondary case definition) averted during an 18-mo follow-up period in children 5–17 mo of
age at enrollment, by study site, ordered by increasing malaria incidence at each site (intention-to-treat population). Clinical malaria
secondary case definition: illness in a child brought to a study facility with a measured temperature of $37.5uC or reported fever within the last 24 h
and P. falciparum asexual parasitemia at a density of .0 parasites/mm3. This definition was used for this analysis because during routine clinical
practice these children would normally receive a full course of anti-malarial treatment. Study sites are ordered from lowest (Kilifi) to highest (Siaya)
incidence of clinical malaria, defined as a measured or reported fever within previous 24 h and parasite density.0 parasites/mm3 (i.e., clinical malaria
secondary case definition), measured in control infants 6–12 wk of age at enrollment during 12 mo of follow-up.
doi:10.1371/journal.pmed.1001685.g011
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Figure 12. Vaccine efficacy against all episodes of clinical malaria (primary case definition) during an 18-mo follow-up period after
dose 3 in infants 6–12 wk of age at enrollment, ordered by increasing malaria incidence at each study site (per-protocol
population). Interaction p-value = 0.1682. The size of each blue square reflects the relative number of participants enrolled at each study site; the
horizontal bars show the lower limit (LL) and upper limit (UL) of the 95% confidence interval. Study sites are ordered from lowest (Kilifi) to highest
(Siaya) incidence of clinical malaria, defined as a measured or reported fever within previous 24 h and parasite density .0 parasites/mm3 (i.e., clinical
malaria secondary case definition), measured in control infants 6–12 wk of age at enrollment during 12 mo of follow-up. VE is VE against all episodes
of clinical malaria meeting the primary case definition, unadjusted for covariates. Clinical malaria primary case definition: illness in a child brought to a
study facility with a temperature of $37.5uC and P. falciparum asexual parasitemia at a density of.5,000 parasites/mm3 or a case of malaria meeting
the primary case definition of severe malaria.
doi:10.1371/journal.pmed.1001685.g012
Figure 13. Vaccine efficacy against all episodes of clinical malaria (primary case definition) during an 18-mo follow-up period after
dose 3 in infants 6–12 wk of age at enrollment, ordered by increasing malaria incidence at each study site (intention-to-treat
population). Interaction p-value= 0.1143. The size of each blue square reflects the relative number of participants enrolled at each study site; the
horizontal bars show the lower limit (LL) and upper limit (UL) of the 95% confidence interval. Study sites are ordered from lowest (Kilifi) to highest
(Siaya) incidence of clinical malaria, defined as a measured or reported fever within previous 24 h and parasite density .0 parasites/mm3 (i.e., clinical
malaria secondary case definition), measured in control infants 6–12 wk of age at enrollment during 12 mo of follow-up. VE is VE against all episodes
of clinical malaria meeting the primary case definition, unadjusted for covariates. Clinical malaria primary case definition: illness in a child brought to a
study facility with a temperature of $37.5uC and P. falciparum asexual parasitemia at a density of .5,000 parasites/mm3 or a case of malaria meeting
the primary case definition of severe malaria.
doi:10.1371/journal.pmed.1001685.g013
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Figure 14. Cases of clinical malaria (secondary case definition) averted during an 18-mo follow-up period in infants 6–12 wk of age
at enrollment, by study site, ordered by increasing malaria incidence at each site (per-protocol population). Clinical malaria secondary
case definition: illness in a child brought to a study facility with a measured temperature of $37.5uC or reported fever within the last 24 h and P.
falciparum asexual parasitemia at a density of .0 parasites/mm3. This definition was used for this analysis because during routine clinical practice
these children would normally receive a full course of anti-malarial treatment. Study sites are ordered from lowest (Kilifi) to highest (Siaya) incidence
of clinical malaria, defined as a measured or reported fever within previous 24 h and parasite density .0 parasites/mm3 (i.e., clinical malaria
secondary case definition), measured in control infants 6–12 wk of age at enrollment during 12 mo of follow-up.
doi:10.1371/journal.pmed.1001685.g014
Figure 15. Cases of clinical malaria (secondary case definition) averted during an 18-mo follow-up period in infants 6–12 wk of age
at enrollment, by study site, ordered by increasing malaria incidence at each site (intention-to-treat population). Clinical malaria
secondary case definition: illness in a child brought to a study facility with a measured temperature of $37.5uC or reported fever within the last 24 h
and P. falciparum asexual parasitemia at a density of .0 parasites/mm3. This definition was used for this analysis because during routine clinical
practice these children would normally receive a full course of anti-malarial treatment. Study sites are ordered from lowest (Kilifi) to highest (Siaya)
incidence of clinical malaria, defined as a measured or reported fever within previous 24 h and parasite density.0 parasites/mm3 (i.e., clinical malaria
secondary case definition), measured in control infants 6–12 wk of age at enrollment during 12 mo of follow-up.
doi:10.1371/journal.pmed.1001685.g015
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Figure 16. Anti-CS antibody geometric mean titers (EU/ml) in RTS,S/AS01 recipients 1 mo after dose 3 in children 5–17 mo of age at
enrollment, ordered by increasing malaria incidence at each study site (per-protocol population). The blue squares reflect the number
of participants in the per-protocol population with a valid assay result available 1 mo after dose 3 in each study site. The horizontal bars show the
lower limit (LL) and upper limit (UL) of the 95% confidence interval. Study sites are ordered from lowest (Kilifi) to highest (Siaya) incidence of clinical
malaria, defined as a measured or reported fever within previous 24 h and parasite density .0 parasites/mm3 (i.e., clinical malaria secondary case
definition), measured in control infants 6–12 wk of age at enrollment during 12 mo of follow-up.
doi:10.1371/journal.pmed.1001685.g016
Figure 17. Anti-CS antibody geometric mean titers (EU/ml) in RTS,S/AS01 recipients 1 mo after dose 3 in children 5–17 mo of age at
enrollment, ordered by increasing malaria incidence at each study site (intention-to-treat population). The blue squares reflect the
number of participants in the per-protocol population with a valid assay result available 1 mo after dose 3 in each study site. The horizontal bars
show the lower limit (LL) and upper limit (UL) of the 95% confidence interval. Study sites are ordered from lowest (Kilifi) to highest (Siaya) incidence of
clinical malaria, defined as a measured or reported fever within previous 24 h and parasite density .0 parasites/mm3 (i.e., clinical malaria secondary
case definition), measured in control infants 6–12 wk of age at enrollment during 12 mo of follow-up.
doi:10.1371/journal.pmed.1001685.g017
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Figure 18. Anti-CS antibody geometric mean titers (EU/ml) in RTS,S/AS01 recipients 1 mo after dose 3 in infants 6–12 wk of age at
enrollment, ordered by increasing malaria incidence at each study site (per-protocol population). The blue squares reflect the number
of participants in the per-protocol population with a valid assay result available 1 mo after dose 3 in each study site. The horizontal bars show the
lower limit (LL) and upper limit (UL) of the 95% confidence interval. Study sites are ordered from lowest (Kilifi) to highest (Siaya) incidence of clinical
malaria, defined as a measured or reported fever within previous 24 h and parasite density .0 parasites/mm3 (i.e., clinical malaria secondary case
definition), measured in control infants 6–12 wk of age at enrollment during 12 mo of follow-up.
doi:10.1371/journal.pmed.1001685.g018
Figure 19. Anti-CS antibody geometric mean titers (EU/ml) in RTS,S/AS01 recipients 1 mo after dose 3 in infants 6–12 wk of age at
enrollment, ordered by increasing malaria incidence at each study site (intention-to-treat population). The blue squares reflect the
number of participants in the per-protocol population with a valid assay result available 1 mo after dose 3 in each study site. The horizontal bars
show the lower limit (LL) and upper limit (UL) of the 95% confidence interval. Study sites are ordered from lowest (Kilifi) to highest (Siaya) incidence of
clinical malaria, defined as a measured or reported fever within previous 24 h and parasite density .0 parasites/mm3 (i.e., clinical malaria secondary
case definition), measured in control infants 6–12 wk of age at enrollment during 12 mo of follow-up.
doi:10.1371/journal.pmed.1001685.g019
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The incidence of SAEs overall was similar in participants in
each group, but the imbalance in reported cases of meningitis,
noted previously [15,16], has persisted, and the difference between
groups has become statistically significant in older children. No
obvious explanation for this association has been found, a
temporal relationship to vaccination is lacking, and biological
plausibility is low. A causal relationship cannot be confirmed or
excluded at this point. The occurrence of meningitis will be
followed closely during the remainder of the trial, with particular
attention paid to the possible impact of a booster dose of vaccine.
As with all large-scale, multicenter trials, this study had some
weaknesses. Although strenuous efforts were made to standardize
clinical and laboratory methods across study sites, there may have
been some variations in the clinical characteristics of cases
recruited at individual centers that could have contributed to the
variations in the level of VE seen across sites. It is possible that
variations in factors such as the prevalence of co-infections
(including HIV), micronutrient deficiencies, or socio-economic status
could have contributed to the heterogeneity in immunogenicity and
VE seen between sites, but these factors were not evaluated
systematically. Finally, the incidence of clinical malaria in
infants was used as an indirect measure of the intensity of
malaria transmission at each site, and it is possible that this is
not a very discriminatory factor, as it may be influenced by
other variables such as the transfer of maternal antibodies
against malaria or access to treatment. A direct measure of
exposure such as the entomological inoculation rate might have
provided a different ranking order between sites. Variations in
the immunogenicity and VE of RTS,S/AS01 between sites
could not be explained solely by variations in the level of
transmission of malaria, but the nature of other factors that may
be involved remains to be determined.
During 18 mo of follow-up, RTS,S/AS01 prevented many
cases of clinical and severe malaria across the 11 sites in the
trial. Despite its lower efficacy in young infants, RTS,S/AS01
also prevented a substantial number of cases of clinical malaria
in young infants. Translated to the population at risk of
malaria, reductions in clinical cases on this scale as a result of
Figure 20. Graphical representation of anti-CS geometric mean titers, vaccine efficacy, and malaria incidence (per-protocol
population). Upper left panel: VE against clinical malaria versus malaria incidence (per-protocol population); lower left panel: anti-CS response
versus malaria incidence (per-protocol population); lower right panel: anti-CS response versus VE against clinical malaria (per-protocol population).
Blue diamonds (infants 6–12 wk) and red squares (children 5–17 mo) represent the study sites. VE (percent) is VE against all episodes of clinical
malaria meeting the primary case definition over 18 mo after dose 3. Anti-CS antibody GMT (EU/ml) was measured at 1 mo after dose 3 in the first
200 participants enrolled at each site. Incidence (n/total [n/T]: episodes per person-year at risk) is the incidence of clinical malaria (primary case
definition) in the control group in the corresponding age category over 18 mo after dose 3.
doi:10.1371/journal.pmed.1001685.g020
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vaccination with RTS,S/AS01 would have a major public
health impact.
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Editors’ Summary
Background. Every year, more than 200 million cases of
malaria occur worldwide, and more than 600,000 people,
mainly children living in sub-Saharan Africa, die from this
parasitic disease. Malaria parasites are transmitted to people
through the bites of infected night-flying mosquitoes and
cause fever that needs to be treated promptly with anti-
malarial drugs to prevent anemia (a reduction in red blood
cell numbers) and life-threatening organ damage. Malaria
transmission can be prevented by using long-lasting
insecticides sprayed on the indoor walls of homes to kill
the mosquitoes that spread the malaria parasite or by
sleeping under insecticide-treated nets to avoid mosquito
bites and further reduce mosquito numbers. Widespread use
of these preventative measures, together with the introduc-
tion of artemisinin combination therapy (an effective anti-
malarial treatment), has reduced the global burden of
malaria by 45% in all age groups, and by 51% among young
children, since 2000.
Why Was This Study Done? Unfortunately, the emer-
gence of insecticide and drug resistance is threatening this
advance in malaria control. Moreover, additional interven-
tions—specifically, effective malaria vaccines—will be need-
ed to eliminate malaria in the large areas of Africa where
malaria transmission remains high. Currently, there is no
licensed malaria vaccine, but RTS,S/AS01, the most advanced
malaria vaccine candidate, is undergoing phase 3 clinical
trials (the last stage of testing before licensing) in infants and
children in seven African countries. The RTS,S Clinical Trials
Partnership reported encouraging results on the efficacy and
safety of RTS,S/AS01 during 12 months of follow-up in 2011
and 2012. Here, researchers report on the 18-month efficacy
and safety of RTS,S/AS01. Vaccine efficacy (VE) is the
reduction in the incidence of a disease (the number of
new cases that occur in a population in a given period)
among trial participants who receive the vaccine compared
to the incidence among participants who do not receive the
vaccine.
What Did the Researchers Do and Find? The researchers
randomly assigned 6,537 infants aged 6–12 weeks and 8,923
children aged 5–17 months to receive three doses of RTS,S/
AS01 or a control vaccine. During 18 months of follow-up,
there were 0.69 episodes of clinical malaria (a high
temperature and parasites in the blood) per person-year
among the children who received all the planned doses of
RTS,S/AS01 (the ‘‘per protocol’’ population) and 1.17
episodes per person-year among the control children—a
VE against clinical malaria in the per-protocol population of
46%. A similar VE was seen in an intention-to-treat analysis
that included all the enrolled children, regardless of whether
they received all of the planned vaccine doses; intention-to-
treat analyses reflect the real-life situation—in which children
sometimes miss vaccine doses—better than per-protocol
analyses. In intention-to-treat analyses, the VE among
children against severe malaria (fever, parasites in the blood,
and symptoms such as anemia) and hospitalization for
malaria was 34% and 41%, respectively. Among infants, the
VE against clinical malaria was 27% in both per-protocol
and intention-to-treat analyses; the vaccine showed no
protection against severe malaria or hospitalization. In both
infants and children, VE waned with time since vaccination.
Across all the study sites, RTS,S/AS01 averted an average of
829 and 449 cases of clinical malaria per 1,000 children and
infants vaccinated, respectively. Finally, the serious adverse
event meningitis (inflammation of the tissues lining the brain
and spinal cord) occurred more frequently in trial partici-
pants given RTS,S/AS01 than in those given the control
vaccine, but the incidence of other serious adverse events
was similar in both groups of participants.
What Do These Findings Mean? These and other
findings show that, during 18 months of follow-up, vaccina-
tion of children and young infants with RTS,S/AS01 prevent-
ed many cases of clinical and severe malaria and that the
impact of vaccination was highest in regions with the
highest incidence of malaria. They indicate, as in the earlier
analysis, that the VE against clinical and severe malaria is
higher in children than in young infants and suggest that
protection wanes over time. Whether or not the vaccine
played a causal role in the observed cases of meningitis
cannot be determined from these results, and the occur-
rence of meningitis will be followed closely during the
remainder of the trial. Other study limitations (for example,
variations in the clinical characteristics of participants from
one center to another) may also affect the accuracy of these
findings and their interpretation. However, by showing that
even a modest VE can avert a substantial number of malaria
cases, these findings suggest that vaccination with RTS,S/
AS01 could have a major public health impact in sub-
Saharan Africa.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001685.
N Information is available from the World Health Organiza-
tion on all aspects of malaria (in several languages),
including malaria immunization; the World Malaria Report
2013 provides details of the current global malaria
situation; the World Health Organization also provides
information on its Global Immunization Vision and
Strategy (in English and French)
N The US Centers for Disease Control and Prevention
provides information on malaria, including a selection of
personal stories about malaria
N Information is available from the Roll Back Malaria
Partnership on the global control of malaria and on
the Global Malaria Action Plan (in English and French);
its website includes a fact sheet about malaria in
Africa
N The latest results from the phase 3 trial of RTS,S are
available on the website of the PATH Malaria Vaccine
Initiative, a global program of the international nonprofit
organization PATH that aims to accelerate the develop-
ment of malaria vaccines and ensure their availability and
accessibility in the developing world
N MedlinePlus provides links to additional information on
malaria and on immunization (in English and Spanish)
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